摘要
目的:观察国产氯比格雷治疗非ST段抬高的急性冠脉综合征(acute coronary syndrome,ACS)患者的长期疗效。方法:符合入选条件的非ST段抬高ACS患者180例,随机分为常规治疗组(对照组)、泰嘉组(加服国产氯吡格雷)、波立维组(加服进口氯吡格雷)。观察胸痛消失率,心电图变化,恶性心律失常发生率及随访1年内的心脑血管联合终点事件。结果:泰嘉组及波立维组病人疗效显著优于对照组(P<0.05),胸痛消失率及心电图改善均优于对照组,而随访1年内的心脑血管联合终点事件和主要的不良反应则没有显著差别(P>0.05)。结论:长期服用国产氯吡格雷对非ST段抬高的ACS患者安全有效。
Objective：To explore the long - term efficacy and safety of domestic clopidogrel in non - ST segment elevating acute coronary syndrome （NSTEACS）. Methods： 180 cases of NSTEACS were randomly divided into three groups： Talcom group was 60cases who were given with domestic clopidogrel;Plavix group was 60cases who were given with imported clopidogrel and control group ; All patients were treated with routine regimen;the therapeutic effects were evalua- ted using the disapparance rate of chest complaint, the change of ECG,the incidence of the cardiac and cerebral events followed up for 12 months and accounted. Results： The effects of Talcom group and Plavix group were significantly higher than those in control group （ P 〈 0.05 ）, but there were not significant diference in cardiac and cerebral events and main adverse effects following 12 months compared with control group（P 〉 0. 05 ）. Conclusion ： The domestic clopidogrel has the same effect and safety as imported preparation in long - term treatment with NSTEACS.
关键词
氯吡格雷
非ST段抬高
急性冠脉综合征
心肌梗死
Clopidogrel
non - ST segmentelevating
acute coronary syndrome
myocardiac infarction
